Document is current
Any future updates will be listed below
-
Authors
Duong, Nathan https://orcid.org/0000-0001-7171-5554
Khan, Dilshad H.
Thomas, Geethu E.
Feng, Yue
Hurren, Rose
Lee, Jong Bok
St-Germain, Jonathan
Drimmer, Lily
Yan, Yongran https://orcid.org/0009-0005-7337-4331
Zhang, Lan Xin
Fang, Karen Kai-Lin
Ling, Dakai
Ma, Mary L.
MacLean, Neil
Gronda, Marcela
Rondeau, Vincent
Brown, Brandon D.
Matellán, Laura https://orcid.org/0000-0002-6897-0148
Jones, Courtney L.
Chang, Hong https://orcid.org/0000-0003-3106-2776
Arruda, Andrea
Xie, Stephanie https://orcid.org/0000-0002-0284-494X
Pelletier, Laurence
Minden, Mark D.
Zhang, Li
Kornblau, Steven M. https://orcid.org/0000-0002-5990-9548
Raught, Brian
Jacobs, Kevin
Jacobs, Max G.
Goede, Daniel
Spadavecchio, Vito
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (CIHR FDN 154282)
Princess Margaret Cancer Foundation
- License Information
-
More Information
Article History
Received: 10 December 2025
Revised: 11 March 2026
Accepted: 27 March 2026
First Online: 17 April 2026
Competing interests
: ADS has received research funding from Takeda Pharmaceuticals and BMS and consulting fees/honorarium from Takeda, Astra Zeneca, BMS and Novartis. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada and the Therapy Acceleration Program of the Leukemia and Lymphoma Society. LZ is a consultant/advisory board member for WYZE Biotech Co., Ltd. JK, MGJ, DG, and VS are employees of Interlinked Therapeutics.
